May 21
|
3 Cash-Heavy Stocks in the Doghouse
|
Apr 24
|
3 Healthcare Stocks with Mounting Challenges
|
Apr 23
|
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025
|
Feb 11
|
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
|
Feb 4
|
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
|
Jan 30
|
7MM PD market to grow by $4.5bn between 2023 and 2033
|
Jan 7
|
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 9.4% CAGR over the last five years
|